Medullary thyroid cancer laboratory findings: Difference between revisions
Jump to navigation
Jump to search
(5 intermediate revisions by 2 users not shown) | |||
Line 7: | Line 7: | ||
* [[Blood]] or imaging tests may be done prior to or in lieu of a biopsy. The following blood tests are conducted: | * [[Blood]] or imaging tests may be done prior to or in lieu of a biopsy. The following blood tests are conducted: | ||
:* [[Thyroid stimulating hormone]] (TSH) | :* [[Thyroid stimulating hormone]] (TSH) | ||
:* [[ | :* [[Thyroxine]] (T4) | ||
:* [[Triiodothyronine]] (T3) | :* [[Triiodothyronine]] (T3) | ||
:* Calcitonin- Calcitonin is required for the diagnosis and follow up of medullary thyroid cancer. It is an important tumor marker. | :* Calcitonin- Calcitonin is required for the diagnosis and follow up of medullary thyroid cancer. It is an important tumor marker. | ||
:* Carcinoembryonic antigen | :* Carcinoembryonic antigen | ||
* Tests for serum thyroid [[antibodies|autoantibodies]] are | * Tests for serum thyroid [[antibodies|autoantibodies]] are done to rule out [[autoimmune]] thyroid disease. | ||
* Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 are tabulated below. | * Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 are tabulated below. | ||
{| style="border: 2px solid #B8B8B8; font-size: 90%; width: 30%;" | {| style="border: 2px solid #B8B8B8; font-size: 90%; width: 30%;" | ||
Line 20: | Line 20: | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Metabolic]]''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Metabolic]]''' | ||
| style="background: #B8B8B8; padding: 5px;"|Decreased [[thyroid stimulating hormone]]<br>Antithyroid antibodies<br>Elevated [[calcitonin]]<br>Decreased calcium | | style="background: #B8B8B8; padding: 5px;"|Decreased [[thyroid stimulating hormone]]<br>Antithyroid antibodies<br>Elevated [[calcitonin]]<br>[[hypocalcemia|Decreased calcium]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Arzu Tatlıpınar1 and İlkay Kartal [Updated 2015].The Evaluation of Thyroid Nodules. ''Journal of Thyroid Disorders & Therapy''.2015.<ref name="İlkay Kartal2014">{{cite journal|last1=İlkay Kartal|first1=Arzu Tatlıpınar|title=The Evaluation of Thyroid Nodules|journal=Journal of Thyroid Disorders and Therapy|volume=04|issue=02|year=2014|issn=21677948|doi=10.4172/2167-7948.1000181}}</ref><small> | | style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Arzu Tatlıpınar1 and İlkay Kartal [Updated 2015].The Evaluation of Thyroid Nodules. ''Journal of Thyroid Disorders & Therapy''.2015.<ref name="İlkay Kartal2014">{{cite journal|last1=İlkay Kartal|first1=Arzu Tatlıpınar|title=The Evaluation of Thyroid Nodules|journal=Journal of Thyroid Disorders and Therapy|volume=04|issue=02|year=2014|issn=21677948|doi=10.4172/2167-7948.1000181}}</ref><small> | ||
Line 45: | Line 45: | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|less than 10pg/mL | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|less than 10pg/mL | ||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|>=100 pg/mL | | style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|>=100 pg/mL | ||
|- | |||
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|Serum [[calcium]] | |||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left| 8.9-10.1 mg/dL | |||
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|> 10.1 mg/dL or < 8.9 mg/dL | |||
|} | |} | ||
Latest revision as of 20:24, 30 November 2015
Medullary thyroid cancer Microchapters |
Differentiating Medullary thyroid cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Medullary thyroid cancer laboratory findings On the Web |
American Roentgen Ray Society Images of Medullary thyroid cancer laboratory findings |
Risk calculators and risk factors for Medullary thyroid cancer laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Laboratory findings consistent with the diagnosis of medullary thyroid cancer include decreased thyroid stimulating hormone, elevated calcitonin, and decreased calcium.
Laboratory Findings
- Blood or imaging tests may be done prior to or in lieu of a biopsy. The following blood tests are conducted:
- Thyroid stimulating hormone (TSH)
- Thyroxine (T4)
- Triiodothyronine (T3)
- Calcitonin- Calcitonin is required for the diagnosis and follow up of medullary thyroid cancer. It is an important tumor marker.
- Carcinoembryonic antigen
- Tests for serum thyroid autoantibodies are done to rule out autoimmune thyroid disease.
- Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 are tabulated below.
Test | Findings |
---|---|
Metabolic | Decreased thyroid stimulating hormone Antithyroid antibodies Elevated calcitonin Decreased calcium |
Adapted from Arzu Tatlıpınar1 and İlkay Kartal [Updated 2015].The Evaluation of Thyroid Nodules. Journal of Thyroid Disorders & Therapy.2015.[1] |
References
|